Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01LCC
|
|||
| Former ID |
DND000006
|
|||
| Drug Name |
PF-4217903
|
|||
| Synonyms |
2-(4-(1-(Quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; PF-04217903; 956905-27-4; PF04217903; PF 04217903; UNII-CYJ9ATV1IJ; CYJ9ATV1IJ; 2-(4-(1-(quinolin-6-ylmethyl)-1H-[1,2,3]triazolo[4,5-b]pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; CHEMBL2001019; 1159490-85-3; aka PF-04217903; C19H16N8O; 2-[4-(3-Quinolin-6-ylmethyl-3H-[1,2,3]triazolo[4,5-b]pyrazin-5-yl)-pyrazol-1-yl]-ethanol; 2-(4-(1-(Quinolin-6-ylmethyl)-1H-(1,2,3)triazolo(4,5-b)pyrazin-6-yl)-1H-pyrazol-1-yl)ethanol; 3zxz; PDMUGYOXRHVNMO-UHFFFAOYSA-N; PF-04217903
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 1 | [1] | |
| Company |
Pfizer
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C19H16N8O
|
|||
| Canonical SMILES |
C1=CC2=C(C=CC(=C2)CN3C4=NC(=CN=C4N=N3)C5=CN(N=C5)CCO)N=C1
|
|||
| InChI |
1S/C19H16N8O/c28-7-6-26-12-15(9-22-26)17-10-21-18-19(23-17)27(25-24-18)11-13-3-4-16-14(8-13)2-1-5-20-16/h1-5,8-10,12,28H,6-7,11H2
|
|||
| InChIKey |
PDMUGYOXRHVNMO-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 956905-27-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID |
29212271, 54248092, 99436977, 103905666, 124756993, 125011823, 125163798, 131480678, 134964423, 135653868, 135685260, 135685261, 135685280, 136340178, 136367293, 136920363, 137276005, 140816092, 143499148, 143499149, 152235007, 152237698, 152258340, 160647178, 162011939, 162037429, 162202551, 163312449, 163345958, 163907943, 164045116, 164764187, 170484567, 172113563, 177748688, 186022475, 198969694, 223402404, 223617434, 223705036, 224378934, 226471317, 247681667, 251963200, 252216038, 252216039, 252451594, 252543331
|
|||
| ChEBI ID |
CHEBI:91425
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00706355) A Study of PF-04217903 in Patients With Advanced Cancer. U.S. National Institutes of Health. | |||
| REF 2 | Sensitivity of selected human tumor models to PF-04217903, a novel selective c-Met kinase inhibitor. Mol Cancer Ther. 2012 Apr;11(4):1036-47. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.